BioHarvest Sciences Inc. Q2 2025 Earnings Call Recap: Key Takeaways

BioHarvest Sciences Inc. reported Q2 2025 earnings, with CEO Ilan Sobel highlighting a pivotal quarter for the company. CFO Bar Dichter and Sobel discussed financial performance, industry prospects, and growth strategies. The company emphasized the importance of adjusted EBITDA, a non-IFRS financial measure, and provided a reconciliation in the earnings release on their website.

BioHarvest Sciences Inc. (NASDAQ: BHST) reported robust financial performance for the second quarter of 2025, with CEO Ilan Sobel and CFO Bar Dichter highlighting significant milestones and growth strategies. The company's revenue grew by 41% year-over-year to $8.5 million, driven by strong core capsule sales and new product introductions [1].

The quarter's highlights included a 28% growth in core VINIA® capsule business and a 100% increase in new product sales. Additionally, BioHarvest secured a new Stage 1 CDMO contract to develop a plant-based fragrance compound, and successfully completed Stage 1 development for a CDMO project with a Nasdaq-listed pharmaceutical company [1].

The company's gross profit margin expanded by 800 basis points to 60%, primarily due to increased manufacturing scale and improved yields. Total operating expenses increased to $6.9 million, driven by higher marketing spend and CDMO services division costs. Despite the increase in expenses, the company reported a net loss of $4.0 million, with an adjusted EBITDA loss of $1.3 million [1].

Looking ahead, BioHarvest expects third-quarter 2025 revenues of at least $9.1 million and aims to reach adjusted EBITDA breakeven in the fourth quarter. The company plans to launch three growth initiatives in the second half of 2025: the 'Health Pros' Professional Affiliate Program, VINIA® BloodFlow Hydration Solution, and an AI-Enabled CDMO Discovery Phase [1].

References:
[1] https://finance.yahoo.com/news/bioharvest-sciences-reports-second-quarter-113000384.html